Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,279,234 papers from all fields of science
Search
Sign In
Create Free Account
Glaucoma, Neovascular
Known as:
glaucoma neovascular
, Glaucomas, Neovascular
, Glaucoma, Neovascular [Disease/Finding]
Expand
A form of secondary glaucoma which develops as a consequence of another ocular disease and is attributed to the forming of new vessels in the angle…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
In Blood
Iris neovascularization
Microbiological
chemically induced
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
P. Mitchell
,
J. Korobelnik
,
+5 authors
Sebastian Wolf
British Journal of Ophthalmology
2009
Corpus ID: 25528803
Background: Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in…
Expand
Review
2008
Review
2008
Blood–retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and management
C. Kaur
,
W. Foulds
,
E. Ling
Progress in retinal and eye research
2008
Corpus ID: 23621301
Review
2007
Review
2007
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
C. Andreoli
,
Joan W. Miller
Current Opinion in Ophthalmology
2007
Corpus ID: 25765314
Purpose of review Recent research has shown that vascular endothelial growth factor (VEGF) is responsible for many ocular…
Expand
Highly Cited
2006
Highly Cited
2006
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
J. Heier
,
A. Antoszyk
,
+8 authors
Naveed B. K. Shams
Ophthalmology (Rochester, Minn.)
2006
Corpus ID: 1092623
Highly Cited
2006
Highly Cited
2006
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.
P. Campochiaro
,
Q. D. Nguyen
,
+9 authors
L. Wei
Human Gene Therapy
2006
Corpus ID: 8302317
Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous…
Expand
Review
2005
Review
2005
Prevalent misconceptions about acute retinal vascular occlusive disorders
S. Hayreh
Progress in retinal and eye research
2005
Corpus ID: 45909022
Highly Cited
2004
Highly Cited
2004
Age-related macular degeneration is the leading cause of blindness...
N. Bressler
Journal of the American Medical Association (JAMA…
2004
Corpus ID: 34677965
ObjectiveTo estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race…
Expand
Highly Cited
2003
Highly Cited
2003
Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics.
Kenichiro Sho
,
Kanji Takahashi
,
+8 authors
M. Uyama
A M A Archives of Ophthalmology
2003
Corpus ID: 22287646
OBJECTIVE To clarify the incidence, demographic features, and clinical characteristics of polypoidal choroidal vasculopathy (PCV…
Expand
Highly Cited
2002
Highly Cited
2002
PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Daniel F. Martin
,
M. Klein
,
+17 authors
Samir C. Patel
Retina
2002
Corpus ID: 29205780
Background Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth…
Expand
Highly Cited
1984
Highly Cited
1984
5-fluorouracil and glaucoma filtering surgery. II. A pilot study.
D. Heuer
,
Richard K. Parrish
,
M. Gressel
,
Elizabeth Hodapp
,
P. Palmberg
,
Douglas R. Anderson
Ophthalmology (Rochester, Minn.)
1984
Corpus ID: 25394388
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE